Home >Beauty Skin Care Natural > OBESITY: CVD Risk Cut With Rejected Weight-Loss Drug - MedPage Today
OBESITY: CVD Risk Cut With Rejected Weight-Loss Drug - MedPage Today
Posted on Thursday, October 6, 2011 by Beauty Skin Care Natural
Using an average of six major risk prediction models, one year of treatment with the combination in low-risk overweight and obese patients reduced the absolute 10-year risk of cardiovascular events by 0.17%, compared with a reduction of 0.05% with placebo (P<0.05), according to Robert Chilton, DO, of the University of Texas Health Science Center at San Antonio.
Significant reductions were also seen with the combination in the predicted 10-year risk of coronary heart disease, MI, and congestive heart failure relative to placebo (P<0.01 for all), he reported at the Obesity Society meeting here.
- Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
- Note that this study demonstrates that weight loss with combination naltrexone/bupropion was associated with improved 10-year risk for overall CV disease, CHD, MI, and CHF as measured by published risk equations.
- Point out that confirmation that reduced CV risk is actually associated with improved outcomes will require a prospective trial.
The findings, he said, provide confidence that the drug combination will show a benefit in an upcoming cardiovascular outcomes trial.
Naltrexone/bupropion has been shown in randomized trials to be effective in getting overweight and obese patients to lose weight compared with placebo.
The FDA, however, went against the recommendations of one of its advisory committees and did not approve the combination because of concerns about increases in blood pressure in patients taking the active treatment.
The agency told the maker of the drug, Orexigen, that it would need to conduct a cardiovascular outcomes trial to ease doubts about safety before the drug could be approved.
Initially, Orexigen was hesitant to conduct such a trial and said it would no longer seek approval for the combination in the U.S., saying the requested trial "is unprecedented and would generate significantly more information than is necessary or feasible."
The company continued meeting with the FDA, however, and said in a Sept. 20 statement that the design requirements for a cardiovascular outcomes trial "are reasonable and feasible and provide the certainty required to reinitiate development of Contrave."
The proposed trial would enroll a population of overweight and obese individuals with an estimated annual risk of major cardiovascular events of 1 to 1.5%.
According to Orexigen, the FDA said that the drug could be approved if an interim analysis of the trial excludes any unacceptable cardiovascular risk.
"Both FDA and Orexigen estimate that such a study would require approximately 87 total events by the interim analysis to enable resubmission of the New Drug Application for approval," according to a statement from the company. "Orexigen estimates that the entire study would require fewer than 10,000 patients and less than two years from study start to the interim analysis."
The trial is expected to start in the first half of 2012.
According to Chilton, he and his colleagues planned to look at the effect of treatment with naltrexone/bupropion on the predicted 10-year risk of cardiovascular events even before the company submitted data to the FDA for consideration.
The analysis reported at the meeting pooled data on 3,363 patients who participated in the phase III Contrave Obesity Research program, which included four randomized, placebo-controlled trials lasting 56 weeks. Patients on active treatment received 32 mg naltrexone SR/360 mg bupropion SR.
The researchers estimated the change in 10-year risk of cardiovascular events after one year of treatment using six established risk prediction tools -- the Framingham, Fremantle, QRisk2, Reynolds, SCORE, and U.K. Prospective Diabetes Study scores.
The patient population had a low cardiovascular risk at baseline. The mean age was about 46, the mean body mass index was 36 kg/m2, and 12 to 13% had type 2 diabetes.
Averaging the six risk scores together, the predicted 1o-year cardiovascular risk at baseline was 5.8% in the drug group and 5.6% in the placebo group.
As seen previously, there was significantly greater weight loss in the active treatment group after one year (7% versus 2.3%, P<0.001).
Using all six of the risk scores, the predicted 10-year risk of cardiovascular disease events dropped to a greater extent with active treatment than with placebo after one year in the overall population, as well as in patients with type 2 diabetes and those without the disease.
There was no significant effect on the predicted risk of ischemic heart disease, cardiovascular mortality, or stroke.
Chilton said that the findings suggest that a cardiovascular outcomes trial will show that the drug combination is safe.
"In a year, we do show risk benefits for cardiovascular reduction in events, so the drug would be something worthwhile," he said, adding that he would prefer having his patients lose weight without drugs.
"Weight loss is very important. If you can do it without the drug, that'd be better yet, but if you need a crutch for a short time this is not a bad option and these are drugs [naltrexone and bupropion] that are both well known," he said. "But I think long term you still need to make a new plan in life and change your entire lifestyle."
Although he did not address the the naltrexone/bupropion combination specifically, Jonathan Purnell, MD, an endocrinologist at Oregon Health & Science University in Portland, said that the recent rejections of three investigational weight-loss drugs -- including topiramate/phentermine (Qnexa) and lorcaserin (Lorqess) -- is "very discouraging."
"We lack tools to effectively help people maintain weight loss, even if we have the time and the resources to talk about lifestyle, and we know that lifestyle alone has a very modest impact on sustained weight loss," said Purnell, a spokesman for the Obesity Society.
"Lacking very effective tools -- and a lot of the studies show that these drugs are effective -- is very frustrating for both us as clinicians as well as patients."
The analysis was funded by Orexigen.
Chilton reported serving as a consultant for Orexigen.
Purnell reported that he had no conflicts of interest.
--
Source: http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHZdTQRC6XH6y9IlG9ul-Qv6wDwJA&url=http://www.medpagetoday.com/MeetingCoverage/OBESITY/28910
~
Manage subscription | Powered by rssforward.com
Blog Archive
-
▼
2011
(2699)
-
▼
October
(651)
- The HCG Diet: Does it really work? - KRCG
- How nutrition affects body hygiene - Myjoyonline.com
- The HCG Diet: Does it really work? - KRCG
- Free Weight Loss Hypnosis For Everyone From The Fa...
- Is Demi Moore on the divorce diet? - Gather Celebs...
- FastPencil PREMIERE Announces "The Social Network ...
- Diet Plan Now Offered Free For Weight Loss - Think...
- Is a Gluten-Free Diet For You? - Patch.com
- Diet Plan Now Offered Free For Weight Loss - Think...
- Lutz reveals 'Immortals' diet - Toronto Sun
- Portfolio Diet – could it be as effective as poppi...
- Obese Family Members of Bariatric-Surgery Patients...
- New Yellow Line Stop May Lead to Congestion - Patc...
- Diet.com Announces Video Host Will Compete in Men'...
- Healthier diet, stronger sperm? - USA Today
- Greensboro Chiropractor Announces Weight Loss Work...
- Local businesses offer weight-loss programs - Lexi...
- Baba Suwe and His New Drug Diet - Nigerian Bulletin
- Demi Moore's dramatic weight loss - The Sun
- Beating cholesterol with the Portfolio Diet - Sydn...
- Chinese scientists solve pandas' bamboo diet myste...
- A New Study Links Diet-Induced Obesity to Male Inf...
- Green diet can help beyond pink month - Hattiesbur...
- The Development Of A Perfect Ferret Food - SmallAn...
- Vivus tried again with FDA for weight-loss drug - ...
- Weight Loss After Surgery Seen in Patient's Family...
- Solta Medical Announces Third Quarter 2011 Results...
- Clair's weight loss transforms her life - Worceste...
- S'pore Immunology Network, Galderma Labs to collab...
- $44 for 30-day hCG w/ aminos weight loss program (...
- Hollywood Weight Loss Secrets: How to Drop the Pou...
- How to still look flawless with acne scars - Trini...
- mbalanced diet poses serious health hazards - Sout...
- The Brentwood Diet - Westside Today
- Rob Kardashian Talks Sexy 'DWTS' Side, Weight Loss...
- TAKING CONTROL OVER YOUR ACNE - NorthFulton.com
- Senator uses Twitter to shed 50 pounds - CNN (blog)
- Even Food Network getting back to basics - Chicago...
- Weight Loss Surgery May Have Healthy Effect on Fam...
- Diet Center Wants to Help Merrick Take the Pounds ...
- Food police: Democratic PAC targets Rep. Sean Duff...
- ASRM: Healthy Diet Boosts Semen Quality - MedPage ...
- Clues About Early Diets Found in Fossilized Teeth ...
- Women who start diet on Tuesday most likely to fai...
- Weight loss after surgery seen in patient's family...
- Jessica Alba sues weight loss company for US$1m - ...
- Weight Loss Surgery May Have Healthy Effect on Fam...
- Tips for healthy weight loss in student athletes -...
- Weight Loss Surgery Benefits Entire Family - New Y...
- Ricki Lake's DWTS weight loss - Winnipeg Free Press
- Create a Heart-Healthy Diet - NorthFulton.com
- Revealed: Why giant pandas can stomach bamboo - CB...
- Rooney Mara On Her Dragon Tattoo Diet, Plus More I...
- Prevent Kidney Stones With An Easy Diet! - Silicon...
- Power of Customization by BIONOVA Skincare - Marke...
- Healthier Diet, Stronger Sperm? - U.S. News & Worl...
- Protein key to curbing overeating and preventing o...
- Going Gluten Free for Weight Loss - First Coast News
- Going Gluten Free for Weight Loss - First Coast News
- Nutrisystem and GlucoFitClub to Pilot the First In...
- Nutrisystem and GlucoFitClub to Pilot the First In...
- Vivus gets back in the race for weight-loss drug O...
- Alkaline or pH diet eases variety of ailments - Ze...
- Vivus tried again with FDA for weight-loss drug - ...
- Acne Drug Spurs Developments in Spinal Cord Treatm...
- UA council still doesn't think Fishinger needs 'ro...
- Sara Davis/Thomas Keller Restaurant Group - NPR (b...
- Diet review: Sugar busters diet - Times of India
- Alkaline or pH diet not only helps loss weight, bu...
- Utah HCG Diet Plan Helps Obese Lower BP - Emailwir...
- Cooking for Special Diets: Where to Get Halloween ...
- Vivus tried again with FDA for weight-loss drug - ...
- Acne collaborates with Daniel Silver - FashionUnit...
- Experts: Milk is not linked to weight loss - Green...
- Registration for weight loss contest takes place t...
- Getting over the weight loss plateau - Times of India
- So much more than weight loss - Regina Leader-Post
- Are you ready for manly soda? - Las Cruces Sun-News
- Is the Dukan diet a health risk? - The Sun
- The alkaline or pH diet, fans claim aids weight lo...
- Looking for a Weight Loss Program That's Right For...
- Wondering if Online Weight Loss Programs Are Right...
- Is the Dukan diet a health risk? - The Sun
- Teach yourself willpower Can't commit to the gym? ...
- The high price of weight loss - Irish Times
- The quality of life diet - Sydney Morning Herald
- Diet determines drug dosage - ScienceAlert
- What Kind of Vegetarian Are You? - Patch.com
- Kate Middleton's Reverse Diet Revealed - Just Don'...
- Healthy Living: Poor diets effecting energy levels...
- DietRedi Announces the Enhancement of Their Weight...
- Sheriff, deputy, others drop pounds with 'Ideal Pr...
- Healthy Skin Care Tips - Five Skincare Guidelines ...
- Weight Loss Firm Which Illegally Used Her Name Fac...
- Daisy Lowe and Matt Smith spotted rowing in the st...
- HCG Tablets Now Offed By True Healthy Products The...
- Nutrition advice: How to avoid common dieting prob...
- Dr Pepper Ten: 'No women allowed' - St. Augustine ...
- The Doctors Chocolate An Antioxidant Rich Dark Cho...
- Do Daisy and the Doctor need a bit of space? Matt ...
-
▼
October
(651)